PWMS News Search Results

Back to NewsWire HomeBack to  Back to PeopleWithMS NewsWire

May 2008 Off the Wire . . .




MN-166 Update

MediciNova has announced positive clinical findings from the completed two-year Phase II clinical trial of orally administered MN-166 for the treatment of multiple sclerosis.

The data showed that sustained disability progression was significantly less likely (by approximately 50%) in those patients receiving MN-166 at either 30 or 60mg per day for 24 months than in those patients receiving the drug for 12 months (p=0.026).

E-Mail the NewsWire e-mail the NewsWire ! ! ! - Handpainted and Customized Canes
 with any news items you discover 

copyright 2003